C4X Discovery Holdings PLC Total Voting Rights (8699D)
July 01 2021 - 6:51AM
UK Regulatory
TIDMC4XD
RNS Number : 8699D
C4X Discovery Holdings PLC
01 July 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Exercise of Warrants,
Exercise of Options,
Block Listing Application
and
Issue of Equity
1 July 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, announces that it has received
notices to exercise options and warrants over, in aggregate,
286,070 new ordinary shares of GBP0.01 in the Company ("Ordinary
Shares"). Further details are below.
Exercise of Warrants
A warrant holder has exercised warrants to subscribe for 178,570
new Ordinary Shares (the "Warrant Shares"), at an exercise price of
28 pence per warrant and for which funds have been received by the
Company.
Exercise of Options
An employee of the Company has exercised options to subscribe
for 107,500 new Ordinary shares (the "Option Shares"), at an
exercise price of 5.58 pence per option and for which funds have
been received by the Company.
Admission and Total Voting Rights
Application has been made for the 178,570 Warrant Shares and
107,500 Option Shares to be admitted to trading on AIM and dealings
are expected to commence on or around 8.00 a.m. on 7 July 2021. The
Warrant Shares and the Options Shares will rank pari passu with the
existing ordinary shares.
Block Listing Application
In addition, an application has also been made for admission to
AIM for a block listing of 106,964,288 ordinary shares of GBP0.01
each in the Company ("Block Listing Shares"), in respect of the
balance of warrants over shares.
The Block Listing Shares will not be allotted immediately, but
rather will be issued and allotted from time to time pursuant to
the exercise of warrants granted and announced on 9 November 2020.
Upon exercise, these Block Listing Shares will be issued as fully
paid and will rank pari passu in all respects with the existing
ordinary shares of the Company.
Total Voting Rights
Upon admission of the Warrant Shares and Option Shares to
trading on AIM, the Company's issued share capital will consist of
226,712,697 ordinary shares. Accordingly, the figure of 226,712,697
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure Guidance and Transparency Rules.
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
neurodegeneration, oncology and addictive disorders . Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio. For more information visit
us at www.c4xdiscovery.com or follow us on twitter
@C4XDiscovery.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRDKDBQKBKDFOK
(END) Dow Jones Newswires
July 01, 2021 06:51 ET (10:51 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2024 to Oct 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Oct 2023 to Oct 2024